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Abstract 
Objectives: To determine the effect of drugs with anti-cholinergic properties on relevant health outcomes.  
Design: Electronic published and unpublished literature/trial registries were systematically reviewed. 
Studies evaluating medications with anti-cholinergic activity on cognitive function, delirium, physical 
function or mortality were eligible.  
Results: Forty-six studies including 60,944 participants were included. Seventy-seven percent of included 
studies evaluating cognitive function (n=33) reported a significant decline in cognitive ability with 
increasing anti-cholinergic load (p<0.05). Four of five included studies reported no association with 
delirium and increasing anti-cholinergic drug load (p>0.05). Five of the eight included studies reported a 
decline in physical function in users of anti-cholinergics (p<0.05). Three of nine studies evaluating 
mortality reported that the use of drugs with anti-cholinergic properties was associated with a trend 
towards increased mortality, but this was not statistically significant. The methodological quality of the 
evidence-base ranged from poor to very good. 
Conclusion: Medicines with anti-cholinergic properties have a significant adverse effect on cognitive and 
physical function, but limited evidence exists for delirium or mortality outcomes.   
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Introduction 
Drugs with anti-cholinergic properties are commonly prescribed for a variety of medical illnesses [1]. 
With a globally ageing population, much of this drug burden falls on the elderly. Ninety percent of older 
adults report taking at least one prescription medication [2]. It has been estimated that 20% to 50% of 
older people have been prescribed at least one medication with anti-cholinergic activity [3]. Younger 
adults may also be prescribed long-term anti-cholinergic treatment for conditions such as asthma or to 
manage the side-effects of medicines used to treat psychiatric disorders [3]. It has been recommended that 
increased care should be taken to avoid the inappropriate prescribing of anti-cholinergic drugs due to the 
wide spectrum of central effects such as the onset of dizziness, sedation, confusion, in addition to 
increasing delirium, causing a decline in cognitive and physical function [1]. Peripheral adverse effects 
are also commonly reported and include dry mouth, dry eyes, constipation, blurred vision and increased 
heart rate [1]. 
Much of the previous evidence has focused on a link between medications with anti-cholinergic 
properties and cognitive function [3,4]. Medications with anticholinergic properties recognized by the 
anti-cholinergic cognitive burden (ACB) scale have been recently correlated with an additional 0.33 point 
decline in Mini-Mental State Examination (MMSE) score over two years [5], a two-fold increase in 
cognitive impairment with as little as 60 to 90 days of use [6], and approximately 50 to 80% increase in 
the risk of incident cognitive impairment over six years [7].  
A decline in cognitive function and the diagnosis of mild cognitive impairment is associated with a 
progression to dementia within five years [8], making primary prevention and avoidance of anti-
cholinergic medications wherever possible, of significant importance as a strategy to protect against 
persistent cognitive decline [9]. Similarly it is well known that functional impairment in older adults 
limits independent living and impacts on their quality of life [10]. Mild cognitive impairment has also 
been attributed to an increased risk of falls, further increasing morbidity and reduced physical function in 
older people [11].  
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This systematic review assesses the empirical research surrounding the effect of increasing anti-
cholinergic load on cognitive function, delirium, physical function and mortality. To the author’s 
knowledge, this is the first systematic review to evaluate the association between medications with anti-
cholinergic properties and delirium or physical function. This paper will also provide an important update 
required to review the current literature on a possible association with cognitive function and mortality.  
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Search Strategy and Selection Criteria 
Search Methods  
A PRISMA compliant systematic review was undertaken [12]. The primary search was conducted of the 
published literature using the electronic databases EMBASE (2002 to 2013) and Ovid MEDLINE (2002 
to 2013) to Week 3 October 2013. The search terms adopted are presented in Table 1. This was adapted 
for the different search databases. 
A secondary search was conducted of the unpublished grey literature and trial registries. The following 
databases were accessed from January 2002 to Week 3 October 2013: Open Grey, the WHO International 
Clinical Trials Registry Platform, Current Controlled Trials and the UK National Research Register 
Archive. An additional search of reference lists from all potentially eligible papers and review articles 
was also undertaken for completeness. 
Eligibility Criteria  
Studies were deemed eligible if they satisfied each of the following criteria: 
a) Studies investigating anti-cholinergic effects on adults. This was confirmed by cross-checking of 
the mentioned drugs against the 2012 updated ACB scale [13]; 
http://www.agingbraincare.org/tools/abc-anticholinergic-cognitive-burden-scale/). All studies 
included were required to indicate the dosage and duration at which medicines were used or how 
the anti-cholinergic load was calculated. 
b) Studies investigating the effect of medicines with anti-cholinergic properties on one of the 
following outcomes: mortality, cognitive function, delirium or physical function. Physical 
function was defined as the ability to perform various activities which require physical capability, 
ranging from self-care (basic activities of daily living (ADL)) to more vigorous tasks which 
require increasing degrees of mobility, strength or endurance such as as walking, ascending stairs, 
carrying shopping or moving from a chair (BRUCE et al, 2009). 
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c) Either randomised controlled trial (RCT), prospective cohort, cross-sectional or prospective case-
controlled studies. 
 
Studies were excluded if: 
a) The primary exposure was not clearly stated or the drug used did not have anti-cholinergic 
properties.  
b) The anti-cholinergic load was based on serum sample analysis alone. 
c) Studies that reported the right exposure but did not report the effect of stated anti-cholinergic 
medicines against the selected outcomes.  
d) Retrospective studies, case reports, journal editorials, literature reviews, clinical audits or studies 
that were not published in the English language. 
e) Animal studies. 
We selected to review only those studies published after 1st January 2002 to capture the results of studies 
evaluating systematic recognition of anti-cholinergic medications through various scales. Other 
systematic reviews have described the relationship between anti-cholinergics and cognitive outcomes 
[3,4,14] and included results prior to 2002. This review therefore updates these previous studies. 
 
Identification of Studies 
Two reviewers (NB, WYC) independently reviewed the study titles and/or abstracts to identify potentially 
eligible studies against the review eligibility criteria. Any disagreements were resolved through 
discussion and adjudicated by a third investigator (CSK).  
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The full text for all potentially eligible studies were gathered and independently re-reviewed by two 
reviewers (NB, WYC) against the eligibility criteria to determine final eligibility. Any disagreements 
were resolved through discussion and adjudicated by three senior reviewers (CSK, CF and IM).  
 
Data Extraction  
Data extraction was independently conducted by five reviewers (NB, WYC, MG, IK, CSK) and verified 
by two senior reviewers (IM, CF). Data extraction was undertaken using a pre-defined data table. Data 
extracted included:  study design; number of participants; year of the study undertaken; selection criteria; 
results of each study with regards to the effect of anti-cholinergic medications on the outcomes of interest;  
significance of the associations were based on the statistical results reported in each study.  
Risk of Bias Assessment  
Two critical appraisal tools were used to assess methodological quality and risk of bias. The Newcastle-
Ottawa scale [15] was used to assess the quality of non-randomised studies. The Cochrane Risk of Bias 
tool [16] was used to assess methodological quality for all RCTs.  
Risk of bias assessments were conducted by two independent reviewers (NB, WYC). In the event of 
disagreement on critical appraisal score, agreement was met through discussion, adjudicated by a third 
reviewer (CSK). 
Data Analysis 
The data extraction table was reviewed to determine the most appropriate analysis technique to answer 
the research question. There appeared considerable study heterogeneity in relation to population diagnosis 
and characteristics, medication and dose, follow-up period, outcome measurement and reporting of data. 
This therefore precluded the adoption of a meta-analysis to pool data. Accordingly, a qualitative narrative 
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review of the literature, answering the research questions, was the most appropriate analysis strategy for 
synthesising trends in findings. 
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Results 
Search Results 
The results of the search strategy are summarised in Figure 1. From a total of 7,078 identified citations, 
133 were deemed potentially eligible. From these 46 studies met the eligibility criteria and were included 
in the final review.  
 
Characteristics of Included Studies 
The characteristics of included studies are summarised in Table 2. The studies consisted of 38 cohort 
studies, six RCTs and two case-control study.  
In total, 60,944 participants, with mean age range of 39.9 to 87.5 years were included. This consisted of 
25,225 males and 32,543 females; cohort gender proportions were not stated in two studies [17,18]. 
Thirty-three studies were conducted in community dwellings and 14 studies in hospital settings, one study 
was conducted across both settings [20]. Participants in the hospital settings were admitted for a variety of 
medical reasons including cancer [21], general frailty/long-term care [22] and acute bladder symptoms 
[23,24]. Supplementary Table 1 illustrates the estimates of anti-cholinergic load or burden to estimate 
the ACB in each included study. 
 
Results of Risk of Bias Assessment 
The results of the critical appraisal and risk of bias assessments are presented in Supplementary Table 2 
to 4. The findings indicate that the evidence-base was largely moderate in methodological quality.  
 
Supplementary Table 3 presents the appraisal results of the single case-control study. The results 
indicated that whilst demonstrating a number of key strengths, the evidence-base was unclear on the 
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validity of the comparison between cases and control participants, with unacceptable non-response rates 
demonstrated for the study cohort. 
 
The Cochrane Risk of Bias tool for RCTs demonstrated the evidence presented with a moderate risk of 
bias. Several studies poorly demonstrated the randomisation procedures, and were limited by incomplete 
analysis of the dataset through intention-to-treat principles, and rarely adjusted analyses for missing data, 
thereby reducing the strength of these statistical analyses. 
Data Synthesis 
A summary of the results of each included study is presented in Table 3 with a more comprehensive 
summary as Supplementary Table 5.  
Anti-cholinergic effect on cognitive function 
Thirty-three studies reported the impact of medications with anti-cholinergic properties on cognitive 
function [5-7,17-19,23-32,37,38,41-45,48,49-52,54-58]. This was evaluated with a number of tools, most 
commonly the MMSE. 
There was a repeated finding of an association between anti-cholinergic medications and a significant 
decline in cognitive ability, as demonstrated by 23 studies [5-7,17-19,23-28,37,38,42-45,48,51,52,54,57]. 
Ten studies reported no significant association between medicines with anti-cholinergic properties and 
cognitive function [29-32,44,49,50,55,56,58]. A number of differences in study design and variable 
definitions may have accounted for the study results, such as differences in medications evaluated (single 
vs. scale-based identification of anti-cholinergics), characteristics of the control group, duration of study, 
and measurement of dose-effect.  
Anti-cholinergic effect on delirium 
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Five studies assessed the impact of anti-cholinergic burden on delirium [20,21,33,36,47]. Only one study 
demonstrated a significant association between drugs with anti-cholinergic properties and delirium [47]. 
Delirium, as assessed by the Delirium Rating Scale (DRS), was more likely in people prescribed 
medicines with anti-cholinergic properties prior to a stroke (OR: 11.3; 95% CI: 1.19 to 108.2) or during 
hospitalisation (OR: 5.82; 95% CI: 1.96 to 17.2), compared to those not prescribed anti-cholinergics [47].  
Luukkanen et al [20], Pandharipande et al [36], Campbell et al [33] and Gaudeau et al [21] reported 
contrary findings, reporting no association between the use of medicines with anti-cholinergic properties 
and delirium.  
Anti-cholinergic effect on physical function 
Eight studies assessed the impact of medications with anti-cholinergic properties on physical function 
[27,34,39,41,50-52,58]. Of five studies reported that anti-cholinergic drugs were associated with reduced 
physical function [27,34,39,51,52].  
Three studies reported no association between ACB and physical function [41,50,58]. Wilson et al [41] 
assessed the level of mobility. They reported that participants could walk without the use of a walking aid 
in 46% of the Drug Burden Index (DBI) category 0, 37.7% of those in the DBI category <1, and 34% of 
those in the DBI category >1. Whilst this is only one aspect of function, this does provide some 
conflicting evidence against the evidence-base. 
Anti-cholinergic effect on mortality 
Nine studies investigated the effect of anti-cholinergic medications on mortality 
[5,11,20,22,35,40,41,46,53].  Six studies reported that the use of drugs with anti-cholinergic properties 
was not statistically associated with increased mortality [11,20,22,40,41,46]. 
Three studies reported contrary findings [5,35,54]. Fox et al [5] reported that after adjusting for key 
variables including baseline MMSE score and number of non-anti-cholinergic medications, every 
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additional point on the ACB scale increased the odds of death by 26% (OR: 1.26, 95%: 1.20 to 1.32) [5]. 
De Luise et al [35] reported a risk ratio of tiotropium use and total mortality of 0.77 (95% CI: 0.56 to 
0.78). However the population considered in this study is notably different from other assessments of 
anti-cholinergic use with a focus on respiratory disease (Table 2). 
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Discussion 
This is the first systematic review to assess the effects of medications with anti-cholinergic properties 
on delirium and physical function, and an important update on cognitive function and mortality. 
The findings indicate that medicines with anti-cholinergic properties have a negative effect on cognitive 
function. The results also indicated no significant association between anti-cholinergic load and either 
mortality or delirium. Single- or limited-drug studies in the past have supported the relationship between 
these medicines and delirium. Using anti-cholinergic drug scales to identify all medications with anti-
cholinergic properties did not appear to confirm such an association. Lastly, this review identified that the 
use of medications with anti-cholinergic properties may be associated with a deterioration in physical 
function.   
The negative effect of increased anti-cholinergic load on adverse cognitive outcomes revealed the 
strongest association throughout the evidence-base. This is in keeping with previous literature reviews 
which have examined the effect of anti-cholinergic burden on cognition [3,4]. A previous review [3] 
noted that the effect of anti-cholinergic drugs on cognition is not always due to one anti-cholinergic drug 
alone, but instead an accumulation of a number of drugs with anti-cholinergic properties is an important 
consideration. Therefore, in this systematic review, it was decided to only include studies which 
quantified this load; either through dosage of the drug used in a RCT, or through using scales to quantify 
ACB.  
Of those studies which did not report a negative effect of increased anti-cholinergic load on cognitive 
function, three of the five studies had relatively shorter follow-up periods (less than two years) or were 
cross-sectional studies. As studies included in the review had a highly variable follow-up period, ranging 
from a few weeks to 12 years, it was difficult to interpret whether the studies with short follow-ups would 
have progressed to report a significant association with cognitive decline should they have included a 
longer follow-up period.  
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There is little support that anti-cholinergic medications increase the risk of mild cognitive impairment, 
which then presents a risk of developing dementia.  In addition there is little, if any, evidence for a non-
reversible impact of anti-cholinergics on cognition.  Consequently the findings of this review on cognition 
should be interpreted with caution until the evidence-base develops in this area. 
In contrast to the continued evidence supporting anti-cholinergic burden and its effect on cognitive 
function, its effect on developing the more acute form of cognitive impairment, delirium, was less 
coherent. Once again these studies were heterogeneous in their quantification of anti-cholinergic load and 
reporting the outcome. Not all studies used the Confusion Assessment Method. This is considered as the 
most accurate diagnostic tool for delirium, advocated by the UK’s National Institute of Clinical 
Excellence (NICE). No association between anti-cholinergic load and delirium was identified within the 
review, in agreement with previous reviews [14]. However, the majority of studies which reported the 
effect of anti-cholinergic medications on physical function reported a significant inverse relationship i.e. 
the higher the anti-cholinergic burden, the lower the physical functioning [27,34,41]. Avoiding anti-
cholinergic medications may therefore preserve and maximise function and prevent acute adverse events 
such as falls.  
The effect of anti-cholinergic burden on mortality was inconclusive. The majority of studies reported no 
statistical association between these variables. However, in a large prospective cohort study, Fox et al [5] 
reported a significant negative effect of increased anti-cholinergic load with increased mortality. Whilst 
this difference may be attributed to heterogeneous included studies, further research should be conducted 
in this area.  Furthermore, these mortality figures should be viewed with caution given that the follow-up 
periods for these studies were insufficient, ranging from 8.9 weeks [40] to 3.3 years [46].  
This paper is the first systematic review to examine the effect of anti-cholinergic medication load 
(excluding those measured by serum anti-cholinergic alone) on cognitive function, physical function, 
delirium and mortality over a large time frame from both published and unpublished sources. However 
the included articles contained a number of limitations. Firstly, due to the data available, the analysis 
15 
 
focused on estimating the presence or absence of significant associations in drug response rather than 
estimating effect size which was not possible in this instance. Secondly the MMSE was the principle 
measure of cognitive change. This may be considered an inappropriate tool for this means in its 
sensitivity and scope given the multi-factorial causes of cognitive impairment, may have been insensitive 
to evaluate the effects of anti-cholinergeric agents.  
A third limitation in this review relates to the approach in accounting for covariates, both confounders and 
effect modifiers, varied considerably across the included studies. There was variability in age and 
seriousness of medical morbidity for which the various drugs were prescribed. Studies did not consider 
sub-clinical disease, which may have confounded any associations. Therefore despite adjusting for many 
health-related factors, the possibility of residual confounders between health status and outcome could not 
be excluded. Another limitation can been seen with the rating of anti-cholinergic exposure varied 
considerably across the included studies. In some studies this was presented on a standard scale, in others 
as a dichotomous (yes/no) scale. Additionally, the reliability of these ratings across studies was difficult 
to establish. Finally, the principle limitation to this review is the variability in study designs. This may be 
a contributing factor to the different effects being reported on physical function, delirium and mortality. 
However, by managing these studies separately during the analysis, and considering the appraisal of study 
quality, the distinction between higher and lower quality evidence was made during the interpretation of 
findings.  
 
Conclusions 
This systematic review provides strong evidence for the adverse effect of increased anti-cholinergic load 
on cognition. The results also show consistent evidence that medicines with anti-cholinergic properties 
may be associated with reduced physical function. The effects of the incidence of delirium and mortality 
appear less well-defined across the literature. Further evidence is required to truly establish their 
association with increasing anti-cholinergic burden.  
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 Table 1. Search terms used for the electronic database searches 
 
 
 
 
 
 
 
 
 
1. (Anticholinergic* or Anticholinergic agent* or Cholinergic antagonist* or 
Anti-cholinergic* or Antimuscarinic* or Antimuscarinic agent* or 
Muscarinic antagonist* or Anti-muscarinic*).mp. [mp=ti, ab, sh, hw, tn, ot, 
dm, mf, dv, kw, nm, kf, ps, rs, ui] (Mortality or death or survival).mp. 
[mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, ps, rs, ui]  
2. (Cognitive function or Cognitive disorder* or Cognitive impairment or 
Dementia or Delirium).mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, 
kf, ps, rs, ui]  
3. (Physical function or Physical activity or Function* or Activity*).mp. 
[mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, ps, rs, ui]  
4. OR/2-4  
5. 1 and 5  
6. Limit 6 to English language  
7. Limit 6 to year="2002 -Current"  
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Table 2: Study design and characteristics of the included studies. 
Study Design; Setting Country Number of 
participants 
Mean 
age 
(yrs) 
% Male Participant Characteristics 
Agar [40] Post-hoc analysis of 
RCT; Hospital and 
community 
Australia 461 72 48 Patients included in Palliative Care Trial with diagnosis of cancer, known date of 
death, Australia - modified Karnofsky Performance Scale (AKPS) score of >60 
at baseline and AKPS score falls <60 at any time during follow up. 
Ancelin [17] Cohort study; 
Community 
France 372 66.2 NS Patients with age >60 years and without dementia at recruitment.  
Boustani [25] Cohort study; 
Community 
USA 1558 77.6 33.6 Patients with age ≥65 years and were African-American. 
Caeiro [47] Case-control study; 
Hospital 
Portugal 74 62 55 Patients included with admission diagnosis of cerebral infarct or intracerebral 
haemorrhage/intraventricular haemorrhage, assessment delirium performed 
within 4 days after stroke onset, a Glasgow Coma Scale score ≥5 on the day of 
the delirium examination. 
Cai [5] Cohort study; 
Community. 
USA 3690 72 30 Patients aged 65 and older who were living independently or with family in a 
community setting. Medication dispensing data defined the exposure, and a two-
stage screening and diagnosis design provided the outcome assessment of 
cognitive impairment 
Campbell [7] Cohort study; 
Community 
USA 1652 81.8 30.9 Patients with age ≥70 years who were African-American, community dwelling, 
had normal cognitive function at baseline and enrolled in Indianapolis-Ibadan 
Dementia Project between 2001 to 2007. 
Campbell [33] Cohort study; Hospital USA 147 76.5 37 Patients with age ≥65 years who were screened to have cognitive impairment, 
admitted to general medical ward, English speaking and delirium-free at 
admission. 
Cancelli [48] Cohort study; 
Community 
Italy 750 75 38.7 Patients with age ≥ 65 years who were living independently or at an institution 
Cao [26] Cross-sectional; 
Community 
USA 932 78 0 Patients included were aged ≥65 years, female Medicare beneficiaries from 1 
September 1992, residents in Baltimore area, self-reported difficulty in 2 or more 
functional domain which included 1) mobility and exercise tolerance 2) upper 
extremity function 3) complex activity heavily involving cognition and sensory 
input 4) basic self care. 
Carriere [45] Cohort study; 
Community 
France  6912 73.7 40.3 Patients were recruited from electoral roll and were community-dwelling, aged 
≥65 years and from 3 French cities. 
Cruce [24] Cross-sectional; 
Hospital 
Canada 88 50.7 31.8 Patients with diagnosis of multiple sclerosis, aged 18-65 years, EDSS score <7.5, 
on stable dosage of classical anti-cholinergic drugs (oxybutynin or tolterodine) 
for bladder dysfunction for at least 6 months prior to assessment and had stable 
multiple sclerosis with no recent relapse or treatment with steroids within the 
past 3 months.  
De Luise [35] Cohort study; Hospital USA 10,603 NS 47.8 Patients admitted between January 1977 to December 2003. 
Drag [30] Cross-sectional study; 
Hospital 
USA 450 67.95 95.3 Patients admitted to Extended Care Centre and had completed the cognitive 
screen, had premorbid IQ ≥70 and did not have delirium or dementia. 
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Fox [5] Cohort study; 
Community 
UK 12,423 75.2 40 Patients were a random sample of ≥65 years old, living at home and institutions. 
Fox [44] Cohort study; 
Community 
UK 244 81 28.6 Patients included standardised diagnosis of dementia, fulfillment of criteria for 
possible or probably Alzheimer's disease with age ≥55 years, had lived in North 
London or Essex (UK) and in contact with family or statutory carer for ≥4 hours 
a week. 
Gaudreau [21] Cohort study; Hospital Canada 261 59.6 56 Patients included if they had histological diagnosis of cancer in consecutive 
admissions to the unit. 
Geller [23] Cohort study; Hospital USA 35 70.4 0 Patients were post-menopausal women, age ≥55 years, seeking treatment for 
overactive bladder and opting for anticholinergic therapy 
Gnijidic [37] Cohort study; 
Community 
Australia 1705 77.2 100 Patients had to be born in English speaking countries or learned English before 
the age of 12 years, community-dwelling men, age ≥70 years, living within the 
defined region of the New South Wales Electoral role whose cognition was intact 
or had mild cognitive impairment or dementia. 
Gnjidic [39] Cross-sectional study; 
Community 
Australia 1705 76.9 100 Patients included were male, aged ≥70 years and resident of South Wales 
Han [27] Cohort study; 
Community 
USA 544 74.4 100 Patients included were male, aged ≥65 years and part of Connecticut Veterans 
Longitudinal Cohort with a diagnosis of hypertension. 
Harvey [31] Randomised, double-
blinded controlled trial; 
Community 
USA 377 39.9 73 Patients had to have a diagnosis of Schizophrenia, Baseline positive and negative 
syndrome scale (PANSS score) of 60-120 and were aged 18-64 years and 
outpatients or inpatients hospitalised for less than 4 weeks. 
Hilmer [34] Cohort Study; 
Community. 
USA 2172 73 47 Patients were community-dwellers with age 70 -79 years who had participated in 
the Health ABC study. 
Kay [29] Randomised, double-
blinded controlled trial; 
Commercial trial centre 
USA 150 67.3 38 Patients were healthy subjects aged ≥60 years, English as first language and were 
able to follow instructions and complete computerised cognitive tests. Excluded 
if anticholinergic use was contraindicated or they suffered from dementia, 
depression or had MMSE ≤27. 
Kersten [49] Randomised Controlled 
Trial; Community 
Norway 87 
 
85 
 
61 
 
Patients were long-term nursing home residents from 22 nursing homes. Have a 
total anticholinergic drug scale (ADS) of greater than or equal 3. Patients were 
not blind, deaf, aphasic, delirious or with severe dementia (Clinical Dementia 
Rating scale of 3) 
Kersten [50] Randomised Controlled 
Trial; Community 
Norway 87 
 
85 
 
61 
 
Patients were long-term nursing home residents from 22 nursing homes. Have a 
total anticholinergic drug scale (ADS) of greater than or equal 3. Patients were 
not blind, deaf, aphasic, delirious or with severe dementia (Clinical Dementia 
Rating scale of 3) 
Kolanowski 
[32] 
Longitudinal-study; 
Community 
USA 87 85.7 23 Patients were included if English speakers, with age ≥65 years, diagnosis of 
dementia using DSM-IV criteria, MMSE score ≥8 but <24, no new psychoactive 
drugs prescribed and presence of behavioural symptoms as reported by staff and 
documented in the latest Minimum Data Set.  
Koyama [51] Cohort study; 
Community 
USA 1484 87.5 0 Patients were community dwelling women who had previously been 
enrolled on the Study of Osteoporotic Fractures from 1986 to 1988. A 
cohort of African-American women were later recruited from 1997 to 
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1998. 
 
Kumpula [22] Cohort study; Hospital Finland 1004 81.3 25 Patients included were living in 1 of 53 long-term care wards in 7 hospitals in 
Helsinki. Exclusion due to incomplete medication data and unavailable mortality 
data. 
Lampela [52] Cohort study; 
Community 
Finland 621 81.7 29.8 Patients were randomly selected ≥75 years from previous cross-sectional data of 
Geriatric Multidisciplinary Strategy for the Good Care of the Elderly (GeMS) 
study with consent to participate. 
Lipton [28] Randomised, double-
blinded crossover 
controlled trial; 
Community 
USA 129 71.2 41.8 Patients were age >65 years, and had to score 10 or less than on the short 
orientation memory and concentration test on enrolment. 
Low [37] Cohort study; 
Community 
Australia 2058 62.5 51.7 Patients were randomly selected from electoral roll. 
Luukkanen 
[20] 
Cohort  Study; Hospital 
and Community 
Finland 425 86.1 18.4 Patients were from geriatric wards, residential or nursing home residents aged 
over 70 years. Diagnosis of dementia using DSM-IV criteria, MMSE score. 
Mangoni [53] Cohort study; Hospital Netherlands 71 85 29.6 Patients were ≥65 admitted with hip fractures and scheduled for surgery. 
Merchant [18] Cross-sectional study; 
Community 
Singapore  2804 NS NS Patients were enrolled in the Singapore Longitudinal Aging Study, community 
dwellers and aged ≥55 years. 
Pandharipande 
[36] 
Cohort study; Hospital USA 198 55.5 52 Patients who were admitted onto medical/coronary ICU and were mechanically 
ventilated, without a baseline neurological disease to confound the assessment of 
delirium.  
Pasina 
[54] 
Cross-sectional study; 
Hospital 
Italy 1232 78.6 49.4 Patients were ≥65 years and admitted into internal medicine and geriatric wards 
participating in the Registry of Polytherapies SIMI (REPOSI study) in 2010. 
Shah [56] Cohort study; 
Community 
USA 896 74.8 30.7 Patients were community-dwelling older clergy without dementia who were 
partiipating in the Religious Orders Study - a longitudinal epidemiologic study of 
aging where participants have been assessed annually for a mean of 10 years. 
Shakakibara 
[55] 
Cohort study; 
Community 
Japan 62 70 40.3 Patients were consecutive subjects in neurology outpatients. All had diagnosis of 
overactive bladder. Exclusion criteria were anticholinergic agents within 2 weeks 
of entry into study, indwelling foley catheters, intermittent catheterisation, post-
void residual urine volume >100 mL, high prostate-specific antigen, acute 
urinary tract infection, closed angle glaucoma, diseases of anti-cholinergic 
contraindication. 
Uusvaara [46] Cohort study; 
community 
Finland  400 80 35 Patients were community dwelling, aged 75-90 years, had a diagnosis of 
cardiovascular disease and were a part of the Drugs and Evidence-Based 
Medicine in the Elderly (DEBATE) study cohort. 
Uusvaara [57] Cohort study; 
community 
Finland 400 80 35 Patients were community dwelling, aged 75-90 years, had a diagnosis of 
cardiovascular disease and were a part of the Drugs and Evidence-Based 
Medicine in the Elderly (DEBATE) study cohort. 
Wagg [42] Randomised, double 
blind, triple-crossover 
trial; Commercial trial 
UK 26 79 54 Patients with age ≥75 years with mild cognitive impairment and body mass index 
of 18-30 kg/m2.  Excluded patients had short-form Geriatric Depression Scale 
score ≥5, and history of urinary retention or current medications to treat 
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centre overactive bladder. 
Wesnes [19] Randomised, double-
blinded, triple crossover 
trial; Commercial trial 
centre 
UK 12 69.1 50 Patients with aged ≥65 years, willing and able to complete study test battery, had 
body mass index 18.0-30.0 kg/m2, 60-100 kg for males, 55-90 kg for females and 
a total score of ≥27 in the MMSE at first visit.  
Whalley [43] Cohort study; 
Community 
UK 281 77.1 57.6 Patients who took part in 1932 Scottish Mental Survey and not known to be in 
treatment for a major illness, had major sensory impairment, were not recently 
bereaved and born in 1921. 
Wilson [41] Cross sectional study 
for RCT data; 
Community 
Australia 602 85.7 29.1 Patients were residents of residential aged care facilities with aged ≥70 years and 
likely to survive for the next 12 months. 
Wilson [11] Cross sectional study 
for RCT data; 
Community 
Australia 602 85.7 29.1 Patients were residents of residential aged care facilities with aged ≥70 years and 
likely to survive for the next 12 months. 
Yeh [58]  Case-control study; 
Community 
Taiwan 71 83.4 100 Patients had diagnosis of dementia as per the DSM-IV in a veteran (residental) 
home. Residents with primary diagnosis of major psychotic disorder, mental 
retardation, recent aggravation of behaviour and psychological symptoms of 
dementia, recent deteriation in helth status or short life expectancy were 
excluded. 
DSM-IV – Diagnostic and Statistical Manual of Mental Disorders-IV; EDSS - Extended Disability Status Scale; ICU – intensity care unit; IQ - intelligence quotients; 
kg – kilograms; kg/m2 – kilograms per square meter; MMSE - Mini Mental State Examination; NS – not stated; PANSS = Positive and Negative Syndrome Scale; 
RCT – Randomised Controlled Trial; UK – United Kingdom; USA – United States of America; yrs - years. 
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Table 3: Executive summary of the results of the included studies by outcome of interest. 
Study  Result Interpretation 
Outcome 1: Cognitive Function 
Ancelin [17] Use of anti-cholinergic drugs is associated with mild cognitive impairment but not increased risk of dementia. 
Boustani [25] Use of anti-cholinergic drugs was associated with a higher risk of  incident cognitive impairment. 
Cai  [6] Use of at least three medications with ACB score of 1 for 90 days, or use of at least one medication with ACB score of 3 for 60 days, increases the risk of mild 
cognitive impairment. 
Campbell [33] Use of anti-cholinergic drugs is associated with a significant increase in incident cognitive impairment. 
Cancelli [48] Use of anti-cholinergic drugs is associated with a significant increase in cognitive impairment. 
Cao [26] Use of anti-cholinergic drugs is associated with a significant risk of cognitive impairment. 
Carriere [45] Use of anti-cholinergic drugs  increases risk for cognitive impairment. 
Cruce [24] Use of anti-cholinergic drugs for bladder symptoms in patients with MS has a negative impact on cognitive function. 
Drag [30] Use of anti-cholinergic drugs is not associated with lower performance on cognitive measures. 
Fox [5] Use of anti-cholinergic drugs is associated with increased risk of cognitive impairment. 
Fox [44] Use of anti-cholinergic drugs in patients with Alzheimer’s disease is not associated with deterioration in cognition. 
Geller [23] Trospium chloride use is associated with significant difference in cognition. 
Gnijidic [37] Use of anti-cholinergic drugs is not associated with increased risk of limitations in cognitive performance, mild cognitive impairment or dementia. 
Han [27] Use of anti-cholinergic medications is associated with reduction in cognitive function. 
Harvey [31] Use of atypical antipsychotics is not associated with significant risk of cognitive impairment. 
Kay [29] Use of darifenacin is not associated with cognitive impairment but oxybutynin leads to cognitive impairment. 
Kersten [49] Reduction of anti-cholinergic medications has no significant effects on cognitive function improvement. 
Kersten [50] Increasing ADS scores is not associated with decrease in cognitive function. 
Kolanowski [32] Use of anti-cholinergic medication is not associated with cognitive impairment. 
Koyama [51] Higher anticholinergic load was significantly associated with poorer cognitive function at 10-year follow-up. 
Lampela [52] Use of anticholinergic medications is associated with cognitive impairment. 
Lipton [28] Use of darifenacin is not associated with significant difference in cognitive function. 
Low [38] Use of anti-cholinergic medication is associated with lower level of complex attention in the young-old but not with greater cognitive decline. 
Merchant [18] Use of anti-cholinergic drugs is associated with increased risk of cognitive impairment. 
Pasina [54] Cumulative effects of anticholinergic drugs as assessed by ACB scale and ARS is associated with cognitive impairment. 
Shah [56] There is a gradation in annual rate of cognitive function decline amongst incident users compared to never users. However there was no significant difference 
between prevalent users and never users. 
Shakakibara [55] Imidafenacin has no effect on cognitive function. 
Uusvaara [57] DAPs may be associated with specific impairments in cognitive functioning. 
Wagg [42] Use of solifenacin is not associated with increased risk of cognitive impairment but significant differences are observed for oxybutynin. 
Wesnes [19] Use of solifenacin is not associated with increased risk of cognitive impairment but significant differences are observed for oxybutynin. 
Whalley [43] Use of anticholinergic drugs is associated with increased risk of cognitive impairment but not dementia. 
Wilson [41] Use of anti-cholinergic drugs is not associated with increased risk of cognitive impairment. 
Yeh [58] Reduction in anticholinergic drugs did not show in cognitive function improvement. 
Outcome 2: Delirium 
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Caeiro [47] Use of anti-cholinergic drugs is associated with increased risk of delirium. 
Campbell [7] Use of anti-cholinergic drugs is not associated with a significant difference in delirium. 
Gaudreau [21] Use of anti-cholinergic drugs is not associated with significant difference in delirium. 
Luukkanen [20] Use of anti-cholinergic drugs is not associated with  a risk of development of delirium. 
Pandharipande [36] Use of anti-cholinergic drugs is not associated with the development of delirium. 
Outcome 3: Physical Function 
Gnjidic [39] No significant difference in chair stands, walking speed, narrow walk, balance and instrument activities of daily living. 
Han [27] Use of anti-cholinergic drugs is associated with poorer performance on the instrument activities of daily living. 
Hilmer [34] Use of anti-cholinergic drugs is associated with poorer performance on the instrument activities of daily living. 
Kersten [50] Higher ADS scores are associated with higher ADL scores with no significant differences. 
Lampela [52] Higher anticholinergic scores are associated with reduced ADL and IADL scores. 
Pasina [51] Cumulative effects of anticholinergic drugs assessed by ACB and ARS scale is associated with functional impairment. 
Wilson [41] Use of anti-cholinergic drugs is associated with greater use of mobility aids. 
Yeh [58] Reduction in anticholinergic burden did not show benefits in functional outcome improvements. 
Outcome 4: Mortality 
Agar [40] Use of drugs with anti-cholinergic properties is not associated with any difference in mortality. 
De Luise [35] Tiotropium use is associated with lower mortality. 
Fox [5] There was a dose-response effect of ACB score associated with mortality at 2 years. 
Kumpula [22] Use of drugs with anti-cholinergic properties is associated with a non-significant trend towards increased mortality. 
Luukkanen [20] Use of anti-cholinergic drugs is not associated with  an increased risk of mortality. 
Mangoni [53] Use of anti-cholinergic drug is associated with increased mortality. 
Uusvaara [46] Use of drugs with anti-cholinergic properties is associated with a non-significant trend towards increased mortality. 
Wilson [11] Use of drugs with anti-cholinergic properties is associated with a non-significant trend towards increased mortality. 
Wilson [41] Use of drugs with anti-cholinergic properties is associated with a non-significant trend towards increased mortality. 
ABS – anti-cholinergic burden score; ACB – anti-cholinergic burden; ADL- activities of daily living; ADS – anti-cholinergic drug scale; ARS – anti-cholinergic risk 
scale; IADL – instrumental activities of daily living; MS – Multiple Sclerosis 
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 Figure 1: PRISMA flow diagram of search strategy results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through database 
searching (n=8098)  
Additional records identified through other sources 
(n=0) 
Records after duplicates removed (n=7078) 
Records screened 
(n=7078) 
Records excluded (n=6945) 
Full-text articles assessed for 
eligibility (n=133) 
Full-text articles excluded (n=87) with reasons: 
 Study aims or methods did not meet inclusion 
and exclusion criteria (n=36) 
 Retrospective design (n=22) 
 Conference abstracts (n=18) 
 Audit (n=2) 
 Editorials and letters (n=2) 
 Protocol (n=2) 
 Literature review (n=3) 
 Not in the English language (n=1) 
 Preliminary results only (n=1) 
 
 
Studies included in qualitative 
synthesis (n=46) 
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Supplementary Tables 1-5 
Supplementary Table 1: The assessment of anti-cholinergic medications and their drug burden for include studies.  
Study Duration of study. Anticholinergic rating 
Agar [40] Mean survival time for the 112 
patients was 8.9 weeks 
Clinician Rated Anti-cholinergic Scale.  Each medicine rated from 0 (no effect) to 3 (marked effect).  Total score was sum 
individual medicine received.  Total burden was stratified by 0-2, 3-5 and 6-9. 
Ancelin [17] 8 years Drugs were categorised having anti-cholinergic burden of 0-3: 
0 = no anti-cholinergic drugs 
1 = no likely effect of anti-cholinergic drugs  
2 = low effect of anti-cholinergic drugs 
3=high effect of anti-cholinergic drugs 
Boustani [25] 5 years Use of any drug with anti-cholinergic activity.  Definition not specified. 
Caeiro [47] NS Anticholinergic drug use (i) before stroke, (ii) during hospitalization but before the assessment were recorded. 
Cai [6] 12 months Medication exposure defined by ACB scale. Exposure was categorized into duration of use of multiple medications with 
low anticholinergic burden or single agent use using cutoff ACB scores of less than or greater than 3. 
Campbell [7] Duration of hospital admission Drugs were classified into ACB scale. This was previously developed from systematic review of literature to identify 
drugs with documented anticholinergic activity. 0=no effect, 1=mild effect, 2=moderate effect, 3=severe effect. 
Campbell [33] 6 years Anti-cholinergic Cognitive Burden scale (ACB) used to identify drugs with possible or definitive anti-cholinergic 
properties. Drugs with no known clinically relevant negative cognitive effects score = 1; score = 2 or 3 for clinically 
definite anti-cholinergic. 
Cancelli [48] NS Drug burden = patients drug were classed as level 1= no likely Anti-cholinergic (ACH) effect, level 2= moderate, level 3= 
high ACH effect. Then level 2 or 3 = considered ACH users, level 1 = non-ACH users.  
Cao [26] 2 years Drug burden was quantified using an index of drug-mediated modification of specific pharmacological effects. Drugs 
were identified in 2004 edition of Mosby’s Drug Consult as having anti-cholinergic effect. Hyperbolic dose-response 
model to normalise pharamcodynamic contribution of a specific drug was used. Drugs can be calculated with an equation. 
Carriere [45] 4 years Inventory of all drugs taken. Reported medicines coded according to World Health Organisation’s Anatomical 
Therapeutic Chemical Classification. Those drugs with anti-cholinergic properties were established from the Theriaque, 
the Banque de Deonnees Automatisee sur les Medicaments and VIDAL classifications 
Cruce [24] 0 Oxybutynin ACB score = 3 
Tolterodine ACB score = 3  
De Luise [35] NS Anatomical therapeutic chemical (ATC) classification system to identify prescriptions for long-acting anti-cholinergic. 
Drag [30] 0 All drugs rated as 0=no known anti-cholinergic properties, 1=potentially anti-cholinergic as evidenced by receptor 
binding studies, 2=anti-cholinergic adverse effect sometimes noted, usually at excessive doses, 3=markedly anti-
cholinergic. Burden score calculated by summing ratings. 
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Fox [5] 2 years ACB Scale. This was previously developed from systematic review of literature to identify drugs with documented anti-
cholinergic activity. 0=no effect, 1=mild effect, 2=moderate effect, 3=severe effect. 
Fox [44] 1.5 years ACB Scale. This was previously developed from systematic review of literature to identify drugs with documented anti-
cholinergic activity. 0=no effect, 1=mild effect, 2=moderate effect, 3=severe effect. 
Gaudreau [21] 4 weeks 23 individual agents with primary or secondary antimuscarinic properties identified. Chosen based on available literature. 
Geller [23] 12 weeks Trospium Chloride ACB Score 3 
Gnijidic [37] NS Drug burden index defined by sum of burden of drugs with sedative effects or anticholinergic effects (Drug dose was used 
in the calculation of drug load where drug burden index = daily dose / (daily dose + minimum recommended dose). 
Gnjidic [39] NS Drug burden index defined by sum of burden of drugs with sedative effects or anticholinergic effects (Drug dose was used 
in the calculation of drug load where drug burden index = daily dose / (daily dose + minimum recommended dose). 
Han [27] 2 years Clinician rated anti-cholinergic score applied to list of medications used in the cohort by two authors of the paper. 0 (no 
effect) to 3 (strong effect). Drugs with no anti-cholinergic effect as a whole were assigned a 0 score. 
Harvey [31] 5 years Drug burden index defined by sum of burden of drugs with sedative effects or anti-cholinergic effects (Drug dose was 
used in the calculation of drug load where drug burden index = daily dose / (daily dose + minimum recommended dose). 
Hilmer [34] 8 weeks Olanzapine ACB score = 3, Risperidone ACB score = 1 
Kay [29] 3 weeks of treatment for each 
arm. Increasing dose strength 
per week. 
Oxybutynin ACB score = 3 
Darifenacin ACB score = 3 
Placebo ACB score = 0   
  
Kersten-1 [50] 11 months Authors reviewed drug regimen and use anticholinergic drug scale (ADS) to assess burden. 0 = no known anticholinergic 
activity (AA), 3 = markedly anticholinergic activity. 
Kersten-2 [51] 11 months Authors reviewed drug regimen and use anticholinergic drug scale (ADS) to assess burden. 0 = no known anticholinergic 
activity (AA), 3 = markedly anticholinergic activity. 
Kolanowski [32] 0 Drugs were classified into ACB Scale. This was previously developed from systematic review of literature to identify 
drugs with documented anti-cholinergic activity. 0=no effect, 1=mild effect, 2=moderate effect, 3=severe effect. 
Koyama [52] 10 years Authors assigned a computed sum of ACB score (0 = no anticholinergic activity; 1 = possible anticholinergic activity; 2 
or 3 = clinically relevant anticholinergic activity) for all potentially inappropriate medications which met the 2003 Beers 
Criteria. 
 
Kumpula [22] 1 year All drugs rated as 0=no known anti-cholinergic properties, 1=potentially anti-cholinergic as evidenced by receptor 
binding studies, 2=anti-cholinergic adverse effect sometimes noted, usually at excessive doses, 3=markedly ACB score 
calculated by summing ratings. 
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Lampela [53] NS Authors reviewed drug regimens and classified them into both ARS (1 = drugs with moderate anticholinergic potential, 
2=strong potential, 3= very strong potential) and ADS (drugs ranked from 0 – no known anticholinergic activity to 3 – 
significant anticholinergic activity). 
Lipton [28] 2 weeks Darifenacin ACB score 3 
Low [37] 4 years  Anti-cholinergic drug scale (ADS): 
0 = no known anti-cholinergic properties 
1 = potential anti-cholinergic activity to 
3 = marked anti-cholinergic activity.  
Luukkanen [20] 2 years Drugs with documented anti-cholinergic properties from the medical literature, and used daily were recorded. Subjects 
receiving 2 or more drugs with anti-cholinergic properties were analysed separately to those with less than 2. 
Mangoni [54] 1 year Authors reviewed drug regimen and assessed ADSS for each patient including ARS (1 = drugs with moderate 
anticholinergic potential, 2=strong potential, 3= very strong potential); ADS (drugs ranked from 0 – no known 
anticholinergic activity to 3 – significant anticholinergic activity); ACB (0=no effect, 1=mild effect, 2=moderate effect, 
3=severe effect.) and DBI (Drug burden index calculated = sum of [dose of the drug in question taken in 24 hours/(dose of 
the drug taken in 24 hours + the 24 hour dose needed to achieve 50% of the maximum effect)], the sum after considering 
all the medication the patient is on was categorised as none = 0, low = <1, high >1) 
Merchant [18] 0 The use of drugs known to possess moderate or strong anti-cholinergic activity was identified from published lists of anti-
cholinergic drugs commonly prescribed. 
Pandharipande 
[36] 
24 hours Prescription of anti-cholinergic medications (i.e. atropine, diphenhydramine, bupropion, hydrochloride, metoclopramide, 
prochloperazine, promethazine) to 32%.  
Pasina [55] 3 months Drug-related anticholinergic burden was calculated using the sum of points for each anticholinergic medication dispensed 
during hospital admission according to the anticholinergic burden (ACB) scale (0= no drugs used, 1 = drugs used but with 
no likely effect, 2 = drugs used with low effect, 3 = drugs used with high effect) and anticholinergic risk scale (ARS) (1 = 
drugs with moderate anticholinergic potential, 2=strong potential, 3= very strong potential).  
Shah [57] 10 years. Drugs were classified into ACB Scale. This was previously developed from systematic review of literature to identify 
drugs with documented anti-cholinergic activity. 0=no effect, 1=mild effect, 2=moderate effect, 3=severe effect. 
Shakakibara 
[56] 
3 months Not yet given anticholinergic rating. 
Uusvaara [46] 3.3 years Drugs used on regular daily basis considered. Drugs with anti-cholinergic properties identified according to previous 
scientific literature. Classified into those using ≥1 drug with anti-cholinergic property (users) and those not using anti-
cholinergics (non-users).  
Uusvaara [58] 0 years Drugs used on regular daily basis considered. Drugs with anti-cholinergic properties identified according to previous 
scientific literature. Classified into those using ≥1 drug with anti-cholinergic property (users) and those not using anti-
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cholinergics (non-users). 
Wagg [42] 21 days of treatment and 21 days 
of washout and crossover so 
patients receive all 3 treatments.  
Assessment was performed at 
end of each treatment period. 
Solifenacin ACB score=3. Oxybutynin ACB score=3. 
Wesnes [19] 31 days. 1 day of treatment and 
14 days washout period and 
crossover so all patients receive 
all 3 treatments.  
Solifenacin ACB score=3. Oxybutynin ACB score=3 
Whalley [43] 12 years Authors reviewed patient self-reported drugs using current literature for anti-cholinergic activity and classified the ACB 
from 0 to 3. (0= no drugs used, 1 = drugs used but with no likely effect, 2 = drugs used with low effect, 3 = drugs used 
with high effect) 
Wilson [41] NS Drug burden index calculated = sum of [dose of the drug in question taken in 24 hours/(dose of the drug taken in 24 hours 
+ the 24 hour dose needed to achieve 50% of the maximum effect)], the sum after considering all the medication the 
patient is on was categorised as none = 0, low = <1, high >1. 
Wilson [11] 1 year Drug burden index calculated = sum of [dose of the drug in question taken in 24 hours/(dose of the drug taken in 24 hours 
+ the 24 hour dose needed to achieve 50% of the maximum effect)], the sum after considering all the medication the 
patient is on was categorised as none = 0, low = <1, high >1. 
Yeh [59] 12 weeks Authors used the CR-ACHS (also known as the ADS). Anticholinergic medications were rated from 0 (no effect) to 3 
(strong effect) 
ACB – Anti-cholinergic burden; Anti-cholinergic activity (ACH); Anti-cholinergic drug scale (ADS), Anti-cholinergic drug scoring system (ADSS), Anticholinergic risk scale (ARS), 
Clinician-rated Anti-cholinergic Score (CR-ACHS); NS – not stated 
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Supplementary Table 2: The Newcastle-Ottawa scale risk of bias assessment for non- randomised included studies. 
Study Representativeness 
of the exposed 
cohort 
 
Selection of 
non-exposed 
cohort 
 
Ascertainment 
of exposure 
Demonstration 
that outcome of 
interest was 
not present at 
start of study 
Comparability 
of cases and 
controls on the 
basis of the 
design or 
analysis 
Ascertainment 
of exposure 
Was follow 
up long 
enough for 
outcomes to 
occur 
Adequacy of follow 
up of cohorts 
Agar [40] X X        
Ancelin [17]     ? X   X  
Boustani [25] X  X  ? ? X  X  X 
Cai [6]  X  X     
Campbell [7] X  X    X  ?   
Campbell [33] X X   X    
Cancelli [48]    X  X  ? ? 
Cao [26] X X  ? X X   X 
Carriere [45]  X  ? X ?   
Cruce [24] X X  ? X ?  X  
De Luise [35] X X  ?  X ? ? ? 
Drag [30] X X  ?  X     
Fox [5]  X  ? ? ? ? ? 
Fox [44]  X   ? X  ? ? ? 
Gaudreau [21] X X  X  X  ?  
Geller [23] X X X  ? X  ? ? X  
Gnijidic [37] X X  ? X  ? ? ? 
Gnjidic [39] X X ? ? X  ? ? ? 
Han [27] X X   X      
Hilmer [34]     X     
Lampela [52]       ? ? 
Kersten [50]     X  X  
Kolanowski [32]  X   X  X  ? ? 
Koyama [51]     ?    
Kumpula [22]  X  X   X   ? 
Low [38]  X X   X   ? 
Luukkanen [20]  X  X X    
Merchant [18]  X  ? ? X ? ? ? 
Mangoni [53] X        
Pandharipande [36]  X  ? X  X X 
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Pasina [54]   ?     X 
Shah [56]         
Shakakibara [55] X   X X ?   
Uusvaara [46] X X  ? ? X   X  X 
Uusvaara [46] X X  ? ? X   NA X 
Whalley [43]  X  ? ?   X 
Wilson [41]  X    X     
Wilson [11]  X    X     
X = inadequate;  = adequate; ? = unclear; NA = not applicable 
 
 Supplementary Table 3: The Newcastle-Ottawa scale risk of bias assessment for included Case-Control study. 
Study Case 
definition 
adequate 
Selection 
of controls 
Definition 
of controls 
Comparability of cases 
and controls on the basis 
of the design or analysis 
Ascertainment of 
exposure 
Same method of 
ascertainment for cases 
and controls 
Non-response rate 
Caeiro [47]    ?   X 
Yeh [58] X  X    X 
X = inadequate;  = adequate; ? = unclear 
 
Supplementary Table 4: The Cochrane Risk of Bias tool results for included RCTs. 
Study Randomisation 
sequence 
generation 
Allocation 
concealment 
Blinding of 
participants and 
personnel 
Blinding 
outcome 
assessors 
Loss to follow up 
(incomplete data) 
Selective reporting 
Harvey [31] X    X  
Kay [29] X    X  
Kersten [49]  X X X X  
Lipton [28] X    X  
Wagg [42] ?    X  
Wesnes [19] ? ? ? ? ?  
X = inadequate;  = adequate; ? = unclear 
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Supplementary Table 5: Comprehensive summary of the results of the included studies by outcome of interest. 
 
 
Study  Outcome 
assessed 
Results Interpretation 
Outcome 1: Cognitive Function 
Ancelin [17] Cognitive 
Function 
Cognitive tests in users vs non-users of anticholinergic drugs:  
Simple reaction time mean (SD) 13.4 (5.9) vs 19.4 (7.0) p= <0.001 
Logical reasoning mean 1.26 (1.0) vs 0.8 (0.8) p = 0.35 
Attention mean 21.6 (5.6) vs 27.5 (10.2) <0.001 
Primary verbal memory mean 5.6 (1.6) vs 4.3 (1.9) p=0.13 
Total number of correct name-face association 2.8 (2.0) vs 1.5 (2.5) p=0.12  
Narrative Recall mean 24.3 (8.6) vs 16.8 (8.9) p<0.01 
Implicit memory mean 2.2 (3.4) vs 1.8 (2.9) p=0.51 
Visuospatial span 4.1 (1.9) vs 3.1 (1.3) p<0.01 
Visuospatial construction 23.4 (2.4) vs 21.4 (4.4) p=0.01 
Naming total correct 9.3 (1.1) vs 8.3 (1.7) p<0.01 
Fluency Total 33.5 (11.4) vs 23.2 (11.6) p<0.01 
Use of anti-cholinergic drugs is associated with 
mild cognitive impairment but not increased risk 
of dementia. 
Boustani [25] Cognitive 
Function 
Use of medication with anticholinergic activity: consistent use of antihistamines 
increased the risk of incident cognitive impairment (odds ratio 2.42, 95% CI: 1.17-
5.04)  
Use of anti-cholinergic drugs was associated with 
a higher risk of  incident cognitive impairment. 
Cai  [6] Cognitive 
Function 
Use of medications with total ACB score of 3 or higher for at least 60 days 
increased the risk of screening positive on the Community Screening Instrument for 
Dementia (OR 2.13; 95% CI: 1.22-3.71); diagnosis of mild cognitive impairment 
by expert panel diagnosis was higher in those using at least 3 medications with 
ACB = 1 (OR 2.63, 95% CI 1.22-5.69) 
Use of at least three medications with ACB score 
of 1 for 90 days, or use of at least one medication 
with ACB score of 3 for 60 days, increases the 
risk of mild cognitive impairment. 
Campbell [33] Cognitive 
Function 
Risk of cognitive impairment among patients receiving definite anti-cholinergics 
OR 1.46 (95% CI: 1.07-1.99) p=0.0181. 
Use of anti-cholinergic drugs is associated with a 
significant increase in incident cognitive 
impairment. 
Cancelli [48] Cognitive 
Function 
ACH users were more likely to have a MMSE score below the 10th percentile than 
non-ACH users (20.5% vs 7.5%; OR 3.18 (1.93-5.23, p<0.001)). ACH users were 
more likely to have Global Deterioration Scale (GDS) score above the 90th 
percentile (21.2% vs 6.70%; OR 3.75 (2.26-6.22)).  
Use of anti-cholinergic drugs is associated with a 
significant increase in cognitive impairment. 
Cao [26] Cognitive 
Function 
Odds ratio adjusted for identified confounders (full model) of association of 
increasing burden of anti-cholinergics with:  
Mini-mental state examination OR 2.4 (95% CI: 1.1-5.1) 
Activities of daily living OR 3.4 (95% CI: 1.7-6.9) 
Chair stands OR 4.2 (95% CI: 2.0-8.7) 
Balance OR 4.9 (95% CI: 2.0-12) 
Walking speed OR 3.6 (95% CI: 1.6-8.0) 
Mobility OR 3.2 (95% CI: 1.5-6.9) 
Use of anti-cholinergic drugs is associated with a 
significant risk of cognitive impairment. 
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Upper extremity function OR 2.7 (95% CI: 1.3-5.4) 
Grip OR 2.4 (95% CI: 1.1-5.3) 
Carriere [45] Cognitive 
Function 
Women adjusted OR:  
Difference from baseline in Isaac Set Test total ≤-6 OR 1.47 (95% CI: 1.16-1.86, 
p=0.002) 
Difference in Benton Visual Retention Test ≤2 OR=1.13 (95% CI: 0.89 to 1.43, 
p=0.33) 
Difference in Trail Making Test A ≥16 OR 1.05 (95% CI: 0.78-1.42) 
Trail Making Test B ≥35 OR 0.98 (95% CI: 0.73-1.31) 
Mini-mental state examination ≤-2 OR 1.26 (95% CI: 1.00-1.60, p=0.05).  
Men adjusted OR:  
Difference in Isaac Set Test total ≤-6 OR 1.03 (95% CI: 0.67-1.59, p=0.89)  
Difference in Benton Visual Retention Test ≤2 OR 1.70 (95% CI: 1.13-2.56, 
p=0.01) 
Difference in Trail Making Test A ≥16 OR 0.84 (95% CI: 0.48-1.46) 
Trail Making Test B ≥35 OR 1.61  (95% CI: 0.98-2.64) 
Mini-mental state examination ≤-2 OR 1.39 (95% CI: 0.92-2.09, p=0.12). 
Use of anti-cholinergic drugs  increases risk 
for cognitive impairment. 
Cruce [24] Cognitive 
Function 
Symbol digital modality test (SDMT) mean in MS patients taking anti-cholinergic 
drugs (ACD) = 36.55 vs MS patients not taking ACD = 49.05 p<0.0001. 
Selective Reminding Test-long-term storage (SRT-LTS) mean in MS patients 
taking ACD = 37.43 vs. MS patients not taking ACD = 45.48 p<0.0019. 
Selective Reminding Test-consistent long-term retrieval mean in MS patients taking 
anticholinergic drugs (ACD) = 26.43 vs. MS patients not taking ACD = 37.17 
p<0.0002. 
Selective Reminding Test-delayed recall mean in MS patients taking 
anticholinergic drugs (ACD) = 7.81 vs. MS patients not taking ACD = 9.65 
p<0.0001. 
Use of anti-cholinergic drugs for bladder 
symptoms in patients with MS has a negative 
impact on cognitive function. 
Drag [30] Cognitive 
Function 
Correlations between anti-cholinergic drug scale burden scores and cognitive scores 
after controlling for premorbid IQ and geriatric depression scale score:  
MMSE 0.01 
Frontal Assessment Battery -0.003 
Judgement 0.10 
Hopkins Verbal Learning Test-Revised immediate -0.02 
Hopkins Verbal Learning Test-Revised delayed 0.03. 
Use of anti-cholinergic drugs is not associated 
with lower performance on cognitive measures. 
 
Fox [5] Cognitive 
Function 
Odds ratio of changes in MMSE scores compared to people with ACB score of 0 
(reference ACB of 0): 
ACB of 1 OR 0.03 (95% CI: -0.11 – 0.17) 
ACB of 2 OR 0.01 (95% CI: -0.20 – 0.21 ) 
ACB of 3 OR -0.15 (95% CI: -0.42 – 0.12)  
ACB of 4 OR -0.34 (95% CI: -0.67 - -0.01) 
Definite use of anti-cholinergic drugs and MMSE decline: OR -0.33 (95% CI: -0.64 
- -0.03) 
Use of anti-cholinergic drugs is associated with 
increased risk of cognitive impairment. 
 
Fox [44] Cognitive 
Function 
Month 18 mean differences for cognitive measures categorised by ABS Score 0 or 
≥1: 
Use of anti-cholinergic drugs in patients with 
Alzheimer’s disease is not associated with 
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Alzheimer’s Disease Assessment Battery-Cognitive subsection OR -1.49 (-1.96 – 
1.06, p=0.42) 
MMSE: OR 0.69 (-0.84 – 2.21, p=0.37) 
Severe Impairment Battery (SIB) 6.23 (-0.26 to 12.73, p=0.06). 
deterioration in cognition. 
Geller [23] Cognitive 
Function 
Change in Hopkins Verbal Learning Test-Revised Form (HVLT-R) score at 4 
weeks after trospium initiation from baseline: mean value 60.0 +/-11.9 p<0.05 vs 
baseline 
Trospium chloride use is associated with 
significant difference in cognition. 
Gnijidic [37] Cognitive 
Function 
DBI 0   
Addenbrookes Cognitive Examination (ACE) <83 1.41 (95% CI: 0.99-2.02)  
Trail Making Task (TMT) not completed 1.05 (95% CI: 0.64-1.75)  
Cognitive Impairment 1.80 (95% CI: 1.17-2.77)  
DBI >0 and <1  
ACE 1.20 (95% CI: 0.8-1.78)  
TMT 1.13 (95% CI: 0.66-1.93)  
Cognitive impairment 1.45 (95% CI: 0.89-2.36)  
DBI≥1  
ACE 2.48 (95% CI: 1.35-4.58)  
TMT 0.73 (95% CI: 0.22-2.41)  
Cognitive impairment 3.52 (95% CI: 1.78-6.93). 
Use of anti-cholinergic drugs is not associated 
with increased risk of limitations in cognitive 
performance, mild cognitive impairment or 
dementia. 
 
Han [27] Cognitive 
Function 
Cognitive function measured using Hopkins Verbal Recall Test.  
Adjusted association between cumulative anti-cholinergic exposure and cognitive 
function (memory): mean effect estimate 0.42 (95% CI: 0.17-0.67, p=0.001).  
  
Use of anti-cholinergic medications is associated 
with reduction in cognitive function. 
Harvey [31] Cognitive 
Function 
Performance on cognitive measures:  
Continuous performance Test (CPT): Risperidone – mean effect size = 0.30; 
olanzapine mean effect size = 0.46. 
 California Verbal Learning Test (CVLT):  
Learning Trial 1: Risperidone – mean effect size = 0.60; Olanzapine = 0.61.  
Learning Trial 15 Risperidone – mean effect size = 0.30; Olanzapine = 0.36. Long-
delay free recall Risperidone = 0.28; Olanzapine = 0.38. 
Recognition discriminability: Risperidone = 0.08; Olanzapine = 0.22.  
Spatial Working Memory Test (SWMT):  
Total correct at 15s: Risperidone = 0.26; Olanzapine = 0.26.  
Total Correct at 5s: Risperidone = 0.0; Olanzapine 0.05.  
Trail making test: Part A: Risperidone 0.07; Olanzapine 0.29.  
Part B: Risperidone 0.08; Olanzapine 0.15.  
Verbal fluency Examination (VFE):  
Category fluency: Risperidone 0.11; olanzapine 0.10.  
Letter fluency: Risperidone 0.07; Olanzapine 0.20.  
Wisconsin Card Sorting Test (WCST)  
Categories: Risperidone 0.17; Olanzapine 0.09.  
Preservative errors: Risperidone 0.08; Olanzapine 0.10. 
Total errors: Risperidone 0.13; Olanzapine 0.05. 
Use of atypical antipsychotics is not associated 
with significant risk of cognitive impairment. 
Kay [29] Cognitive Accuracy of delayed recall on the Name-Face Association Test at 3 weeks Use of darifenacin is not associated with 
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Function compared to placebo (least square mean): 
Darifenacin 15 mg: OR -0.06 (95% CI: -1.08 – 0.96), p=0.022 
Oxybutynin ER 20 mg: OR -1.30 (95% CI: -2.28 - -0.31), p=0.011 
Immediate memory recall (least square mean): 
Name-face association: Darifenacin 15 mg (-0.30) Oxybutynin ER 20 mg (-0.74) 
First-last name association: Darifenacin 15 mg (-0.00) Oxybutynin ER 20 mg (-
0.32) 
Facial recognition: Darifenacin 15 mg (0.29) Oxybutynin EF 20 mg (-1.37) 
Delayed memory recall (least square mean): 
First-last name association: Darifenacin 15 mg (0.18) Oxybutynin EF 20 mg (-0.39) 
Misplaced objects: Darifenacin 15 mg (-0.73) Oxybutynin EF 20 mg (-1.03) 
Visual attention (least square mean): 
Matching to sample: Darifenacin 15 mg (-1.94) Oxybutynin EF 20 mg (-0.11) 
Visual sequence comparison: Darifenacin 15 mg (-2.33) Oxybutynin EF 20 mg (-
1.09) 
Information-processing speed (least square mean): 
Divided attention (sequence comparison speed, dual condition): Darifenacin 15 mg 
(0.30) Oxybutynin ER 20 mg (0.06)  
Divided attention (sequence comparison efficacy): Darifenacin 15 mg (-2.19) 
Oxybutynin ER 20 mg (0.21) 
Divided attention (sequence comparison accuracy): Darifenacin 15 mg (2.21) 
Oxybutynin ER 20 mg (-0.17) 
Visual sequence comparison: Darifenacin 15 mg (0.12) Oxybutynin ER 20 mg 
(0.01) 
Divided attention (single task premature hits): Darifenacin 15 mg (0.12) 
Oxybutynin ER 20 mg (-0.27) 
Divided attention (task reaction time, dual condition): Darifenacin 15 mg  (0.02) 
Oxybutynin ER 20 mg (0.06) 
Divided attention (premature hits, dual condition): Darifenacin 15 mg (0.12) 
Oxybutynin ER 20 mg (-0.27) 
Psychomotor/reaction time: Darifenacin 15 mg (-0.03) Oxybutynin ER 20 mg 
(0.01) 
cognitive impairment but oxybutynin leads to 
cognitive impairment. 
 
Kersten [49] Cognitive 
Function 
There was significant reduction in total ADS scores at baseline and at 8-week 
follow-up from 4 to 2 (p<0.0001) in intervention group.  
There was no significant mean difference between baseline and 8-week follow-up 
of CERAD immediate recall 0.54 (-0.91, 2.05) p=0.48; CERAD delayed recall -
0.23 (-0.85, 0.38) p= 0.46; CERAD recognition 0.77 (-0.39, 1.94) p=0.19; MMSE 
0.39 (-0.96, 1.75) p=0.57 
Reduction of anti-cholinergic medications has no 
significant effects on cognitive function 
improvement. 
Kersten [50] Cognitive 
Function 
Adjusted mean differences in comparison to ADS = 3 
CERAD immediate recall, number of words: ADS = 4: 1.3 (-1.1, 3.8); ADS = 5: 1.0 
(-1.8, 3.7); ADS ≥6: 0.2 (-2.9, 3.4) 
CERAD verbal delayed recall, number of words: ADS = 4: 0.2 (-1.1, 1.7); ADS = 
Increasing ADS scores is not associated with 
decrease in cognitive function. 
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5: 0.1 (-1.4, 1.6); ADS ≥6: -0.1 (-1.9, 1.6) 
CERAD verbal recognition, number of words: ADS = 4: -1.2 (-3.1, 0.7); ADS = 5: -
0.6 (-2.7, 1.4); ADS ≥ 6: 0.1 (-2.0, 2.3) 
MMSE: ADS=4: 1.1 (-2.9, 2.8); ADS=5: 0.1 (-2.9, 2.8); ADS ≥6: -0.1 (-3.4, 3.1)  
Kolanowski 
[32] 
Cognitive 
Function 
There were no significant associations between ACB measures and mean 
engagement: Any ACB (p=0.302), any ACB 3 (p=0.126), ACB 3 score (p=0.412), 
Total ACB score (p=0.640).  
There was no significant difference between those with any ACB drug and those 
with none (p=0.350) or between those receiving any ACB 3 drug and those who did 
not p=0.877. 
Use of anti-cholinergic medication is not 
associated with cognitive impairment. 
Koyama [51] Cognitive 
Function 
Rate of change in mean  ACB score at 10 year follow-up for cognitive status: 
Dementia 0.67 (SE=0.13); MCI 0.50 (SE=0.11); Normal 0.34 (SE=0.07) p<0.02  
Higher anticholinergic load was significantly 
associated with poorer cognitive function at 10-
year follow-up. 
Lampela [52] Cognitive 
Function 
Higher anticholinergic scores associated with decrease in MMSE (p<0.01). In 
dementia patients anticholinergic scores were found to have no associateion with 
MMSE.  
Use of anticholinergic medications is associated 
with cognitive impairment. 
Lipton [28] Cognitive 
Function 
Memory scanning sensitivity: least squares mean differences from baseline were 
0.056 (SD: 0.017) in Darifenacin group compared to 0.032 (SD: 0.017) in placebo 
group. 
Choice reaction time speed (m/s): least squares mean differences from baseline 
were 3.89 (SD: 4.72) in Darifenacin group compared to 2.70 (SD: 4.46) in placebo 
group.  
Delayed Word recognition sensitivity: least squares mean change from baseline was 
-0.003 (SD: 0.021) in Darifenacin group compared to 0.016 (SD: 0.020) in placebo 
group. 
Use of darifenacin is not associated with 
significant difference in cognitive function. 
 
Low [38] Cognitive 
Function 
Adjusted association between anticholinergic medication use and cognitive 
function:  
Simple reaction time F=0.1 p=0.733 
Choice reaction time F=4.1 p=0.043 
Immediate recall F=0.1 p=0.701 
Delayed recall F=0.000 p=0.989 
Digits backwards F=0.9 p=0.347 
Mini-mental state examination F=1.9 p=0.167 
Symbol digits modalities test F=7.1 p<0.008 
Use of anti-cholinergic medication is associated 
with lower level of complex attention in the 
young-old but not with greater cognitive decline. 
Merchant [18] Cognitive 
Function 
Adjusted association between use of ACB drugs and cognitive impairment: OR  
2.66 (1.06-6.68). 
Use of anti-cholinergic drugs is associated with 
increased risk of cognitive impairment. 
Pasina [54] Cognitive 
Function 
Adjusted Mean Short Blessed Test (SBT)  of patients treated with anticholinergic 
drugs according to ACB scale was 9.2 (95% CI 8.6-9.9) than those not treated with 
anticholinergic drugs 8.5 (95% CI 7.8-9.2) (p=0.05).  
Adjusted Mean SBT of patients treated with anticholinergic drugs according to 
ARS was 9.9 (95% CI 8.7-11.2) than those not treated with anticholinergic drugs 
8.8 (8.2-9.4) (p=0.07) 
Cumulative effects of anticholinergic drugs as 
assessed by ACB scale and ARS is associated 
with cognitive impairment. 
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Shah [56] Cognitive 
Function. 
Z score is calculated using a battery of 19 cognitive function tests in addition to the 
MMSE. No significant difference between prevalent and non-prevalent users. 
Annual rate of change = -0.007 z score units/year, SE = 0.012, p=0.6. Incident users 
in non-prevalent group have a more rapid dcline (difference = -0.034 z-score 
units/year, SE=0.008 p<0.001 compared to never users. 
There is a gradation in annual rate of cognitive 
function decline amongst incident users 
compared to never users. However there was no 
significant difference between prevalent users 
and never users. 
Shakakibara 
[55] 
Cognitive 
Function 
Baseline cognitive function = mean MMSE 21.8, mean FAB 10.7, mean ADAS-cog 
14.8.  
At 3 month follow-up mean MMSE 22.1; mean FAB 11.1; mean ADAS-cog 14.4. 
No significance difference calculated. 
Imidafenacin has no effect on cognitive function. 
Uusvaara [57] Cognitive 
Function 
CERAD battery test: Low verbal fluency: DAP users 31.7% vs. non-users 18.1% 
p=0.008; Low naming test: Users 51.2% vs non-users 33.3% p=0.002; Low MMSE 
DAP users 24.7% vs. non-users 12.4% p=0.008; Low wordlist learning task: users 
53.9% vs. 44.8% p=0.11; Low word list recall: Users 44.1% vs. 40.0% p=0.47; low 
wordlist recognition: users 35.3% vs non-users 32.4% p=0.59; low recall of 
constructional praxis: users 24.7% vs. non-users 19.0% p=0.24; low clock drawing 
users 40.9% vs non-users 31.7% p=0.10 
After adjustment for age, sex and education low verbal fluency and naming 
remained statistically significant. 
DAPs may be associated with specific 
impairments in cognitive functioning. 
Wagg [42] Cognitive 
Function 
Solifenacin difference in:  
Power of attention -20.99 (95% CI: -68.58 – 26.61) 
Continuity of attention -0.51 (95% CI: -2.29 – 1.28) 
Quality of working memory -0.04 (95% CI: -0.21 – 0.13) 
Quality of episodic memory 4.66 (95% CI: -14.86 – 24.17) 
Speed of memory -77.92 (95% CI: -372.81 – 216.98)  
  
Oxybutynin difference in:  
Power of attention 17.51 (95% CI: -28.85 – 63.87)  
Continuity of attention -0.79 (95% CI: -2.12 – 0.54) 
Quality of working memory -0.05 (95% CI: -0.19 – 0.10) 
Quality of episodic memory -1.46 (95% CI: -18.98 – 16.06) 
Speed of memory 157.78 (95% CI: -182.02 – 497.58) 
Use of solifenacin is not associated with 
increased risk of cognitive impairment but 
significant differences are observed for 
oxybutynin. 
Wesnes [19] Cognitive 
Function 
Solifenacin difference in:  
Power of attention -0.44 (95% CI: -38.58 – 37.69) 
Continuity of attention 1.19 (95% CI: -0.47 – 2.85) 
Quality of working memory 0.07 (95% CI: -0.18 – 0.31) 
Quality of episodic secondary memory 9.21 (95% CI: -11.96 – 30.37) 
Speed of memory -114.71 (95% CI: -346.05 – 116.63) 
  
Oxybutynin difference in:  
Power of attention 46.50 (95% CI: 8.05 – 84.95) 
Continuity of attention -3.04 (95% CI: -4.70 - -1.38) 
Quality of working memory -0.44 (95% CI: -0.68 - -0.20) 
Quality of episodic secondary memory -16.86 (95% CI: -37.97 – 4.26) 
Speed of memory 199.68 (95% CI: -32.74 – 432.11) 
Use of solifenacin is not associated with 
increased risk of cognitive impairment but 
significant differences are observed for 
oxybutynin. 
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Whalley [43] Cognitive 
Function 
Raven progressive matrices (mean):  
No drugs 30.8 (9.4) 
Prescribed drugs 28.6 (8.3) 
Mild-moderate exposure to anticholinergic 30.6 (8.5) 
Strong exposure to anticholinergic 21.6 (7.1), 
Univariate analysis of variance F=2.89 p=0.038.  
Block design (mean):  
No drugs 20.1 (6.9) 
Prescribed drugs 20.5 (7.2) 
Mild-moderate exposure to anticholinergic 18.5 (7.3) 
Strong exposure to anticholinergic 12.6 (5.8) 
Univariate analysis  of variance F=3.22 p=0.025.  
Auditory verbal learning test (mean): 
No drugs 47.6 (14.1) 
Prescribed drugs 48.6 (12.5) 
Mild-moderate exposure to anticholinergic 48.8 (12.0) 
Strong exposure to anticholinergic 44.5 (9.9) 
Univariate analysis of variance F=0.28 p=0.838.  
Mini-mental state examination (mean):  
No drugs 28.6 (1.9) 
Prescribed drugs 28.1 (2.3) 
Mild-moderate exposure to anticholinergic 28.2 (1.4) 
Strong exposure to anticholinergic 26.8 (1.4) 
Kruskal-Wallis p=0.021 
Use of anticholinergic drugs is associated with 
increased risk of cognitive impairment but not 
dementia. 
Wilson [41] Cognitive 
Function 
Mini-mental state examination score (MMSE) were:  None DBI: 23.7 (5.4); Low 
DBI: (>0 and <1): 22.9 (5.8); High DBI: (>1): 23.7(5.7)  
Use of anti-cholinergic drugs is not 
associated with increased risk of cognitive 
impairment. 
Yeh [58] Cognitive 
Function 
Difference in CR-ACHS at 12-week follow up: Intervention group = -0.5 vs 
Reference group = 0.1 p=0.014 
Difference in MMSE at 12-week follow-up: Intervention group = -0.8 vs Reference 
group = -0.4 p=0.734 
Reduction in anticholinergic drugs did not 
show in cognitive function improvement. 
Outcome 2: Delirium 
Caeiro [47] Delirium Patients with delirium were more likely to have use of ACH before stroke OR 11.3 
(95% CI: 1.19-108.2) and more likely to have ACH during hospitalization OR 5.82 
(95% CI: 1.96-17.2). 
Use of anti-cholinergic drugs is associated with 
increased risk of delirium. 
Campbell [7] Delirium Risk of delirium among those prescribed definite anti-cholinergic medications: OR 
0.43 (95% CI: 0.11 – 1.63). 
Use of anti-cholinergic drugs is not associated 
with a significant difference in delirium. 
Gaudreau [21] Delirium Unadjusted HR = 1.22 (0.65 to 2.30) p=0.53. Adjusted HR for history of delirium 
and liver metastases = 1.38 (0.73 to 2.60) p=0.32 
Use of anti-cholinergic drugs is not associated 
with significant difference in delirium. 
Luukkanen 
[20] 
Delirium Use of anti-cholinergic did not predict delirium (OR: 1.67; 95% CI: 0.87-3.21). Use of anti-cholinergic drugs is not associated 
with  a risk of development of delirium. 
Pandharipande 
[36] 
Delirium The administration of anti-cholinergic was not associated in univariate analysis 
(p=0.54) or multivariate analysis (p=0.82) with delirium. 
Use of anti-cholinergic drugs is not associated 
with the development of delirium. 
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Outcome 3: Physical Function 
Gnjidic [39] Physical Function Adjusted risk of functional outcomes with anticholinergic drug use: chair stands 
0.35 (95% CI: -0.43-1.12); walking speed -0.02 (95% CI: -0.05-0.01); narrow walk 
-0.01 (95% CI: -0.04-0.02); balance -0.03 (95% CI: -0.11-0.05); grip strength -1.08 
(95% CI: -1.99 - -0.17); instrument activities of daily living 0.13 (95% CI: -0.03-
0.29)  
No significant difference in chair stands, walking 
speed, narrow walk, balance and instrument 
activities of daily living. 
Han [27] Physical Function Adjusted instrumental activities of daily living: mean effect estimate: 0.10 (95% CI: 
0.04-0.17, p=0.001).  
Use of anti-cholinergic drugs is associated with 
poorer performance on the instrument 
activities of daily living. 
Hilmer [34] Physical Function Multiple regression for association of DBI at baseline and at 6 years (B and t-
value): SPPB: -0.29 (p=0.008). Usual gait speed -0.04 (p=0.001). Grip strength -
0.56 (p=0.08). 
The SPPB summary performance score (total 0-12) adds scores (0-4) for tests of 
standing balance, usual gait speed, and time to complete 5 repeated chair stands.7 
Higher scores represent better function. 
 
Use of anti-cholinergic drugs is associated with 
poorer performance on the instrument 
activities of daily living. 
Kersten [50] Physical 
Function. 
Adjusted mean differences in anticholinergic end points between different 
subgroups of ADS score (4, 5 and ≥6) with reference to ADS score = 3. 
 
Barthel’s index of activity of daily living: ADS = 4: 4.5 (-10.5, 19.6); ADS = 5: 
15.67 (-1.3, 32.6); ADS ≥6: 19.11 (-0.2, 30.4) 
Higher ADS scores are associated with higher 
ADL scores with no significant differences. 
Lampela [52] Physical Function Higher anticholinergic scores associated with decrease in short-distance vision 
(p<0.01), ADL and IADL (p<0.001). In dementia patients anticholinergic scores 
were found to have negative association with short distance vision (p<0.01), IADL 
(p<0.01).  
Higher anticholinergic scores are associated with 
reduced ADL and IADL scores. 
Pasina [51] Physical 
Function. 
Adjusted mean BI with anticholinergic use according to ACB = 83.5 (95% CI 81.9-
85.0) compared to those without anticholinergic use = 96.3 (84.4-88.1) (p=0.03). At 
3 month follow up: adjusted mean BI score for users = 82.8 (95% CI 84.2-89.2); 
non-users = 86.7 (95% CI 84.2-89.2) (p=0.02) 
 
Adjusted mean BI with anticholinergic use according to ARS = 79.0 (95% 74.9-
83.0) compared to no anticholinergic use = 85.2 (95% CI 84.0-86.4) (p=0.006). At 
3 month follow up: adjusted mean BI score for users = 76.9 (95% CI 71.8-82.1); 
non-users =  85.2 (95% CI 83.5-86.9) (p=0.003) 
Cumulative effects of anticholinergic drugs 
assessed by ACB and ARS scale is associated 
with functional impairment. 
Wilson [41] Physical Function Functional status: No walking stick/frame use: DBI 0 87/189 (46%), >0 and <1 DBI 
98/260 (37.7), DBI >1 52/153 (34%) 
Use of anti-cholinergic drugs is associated with 
greater use of mobility aids. 
Yeh [58] Physical 
Function. 
Difference in BI at 12-week follow-up: Intervention group = -0.5 vs Reference 
Group = -4.3 (p=0.116) 
Reduction in anticholinergic burden did not show 
benefits in functional outcome improvements. 
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Outcome 4: Mortality 
Agar [40] Mortality A log-rank test demonstrates there was no evidence that survival differed between 
the 3 groups (p>0.05). 
Use of drugs with anti-cholinergic properties is 
not associated with any difference in mortality. 
De Luise [35] Mortality Risk ratio of tiotropium use and total mortality OR 0.77 (95% CI: 0.56-0.78)  Tiotropium use is associated with lower 
mortality. 
Fox [5] Mortality Odds ratio for mortality reported after adjusting for age, sex, baseline MMSE, 
education, social class, no. of non-anticholinergic medications, health conditions. 
Overall mortality OR = 1.26 (95% CI: 1.20-1.32) 
Definite anti-cholinergics OR = 1.68 (95% CI: 1.30-2.16) 
Possible anti-cholinergics OR = 1.56 (95% CI: 1.36-1.79). 
There was a dose-response effect of ACB score 
associated with mortality at 2 years. 
Kumpula [22] Mortality Cox hazards ratio for mortality is: ARS 1-2 vs 0: HR 1.08 (95% CI: 0.84-1.41); 
ARS ≥3 vs 0: HR 1.05 (95% CI: 0.75-1.46) 
Use of drugs with anti-cholinergic properties is 
associated with a non-significant trend towards 
increased mortality. 
Luukkanen 
[20] 
Mortality For whole cohort, use of anti-cholinergic was not an independent predictor of 
mortality (HR: 1.12; 95% CI: 0.75-1.68). This remained the same for those with 
pre-study diagnoses of dementia (HR: 1.41; 95% CI: 0.85-2.34). 
Use of anti-cholinergic drugs is not associated 
with  an increased risk of mortality. 
Mangoni [53] Mortality Total all cause mortality at 3 months = 12.7%. Pre-admission cognitive impairment, 
in-hospital delirium, Katz ADL index, CCI, LOS, ARS score HR = 1.6 (1.2-2.2) 
p=0.004 and DBIantichol HR = 4.5 (1.2-16.7) p=0.02 were significantly associated. 
Pre-admission cognitive impairment and anticholinergic risk scale score HR = 2.2 
(1.2-3.7) p=0.006 were independent predictors.  
 
Total all-cause mortality at 1-year was 25.4%. Living at home, in-hospital delirium, 
Katz index score, CCI, ARS HR = 1.4 (1.1-1.8) p=0.005 and DBIantichol 3.2 (1.1-9.4) 
p=0.04 were significantly associated. Living at home, in-hospital delirium and LOS 
were independent predictors. 
Use of anti-cholinergic drug is associated with 
increased mortality. 
Uusvaara [46] Mortality Adjusted Cox hazard ratio for risk of mortality with anticholinergic use: HR 1.57 
(0.78 - 3.15, p=0.20).  
Use of drugs with anti-cholinergic properties is 
associated with a non-significant trend towards 
increased mortality. 
Wilson [11] Mortality Risk of mortality with low DBI and high DBI vs no DBI HR: Low DBI: HR 1.13 
(0.82-1.57); High DBI: HR 1.19 (0.82-1.74) 
Use of drugs with anti-cholinergic properties is 
associated with a non-significant trend towards 
increased mortality. 
Wilson [41] Mortality Multivariate HR for 1 year survival: Low DBI vs none: HR 1.13 (0.82-1.57); High Use of drugs with anti-cholinergic properties is 
associated with a non-significant trend towards 
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DBI vs none: HR 1.19 (0.82-1.74) increased mortality. 
 
ABS – anti-cholinergic burden score; ACB – anti-cholinergic burden; ADL – activities of daily living; ADS – anti-cholinergic drug scale; ARS – anti-cholinergic risk scale; BI – Barthel’s index; CCI – 
Charlson’s Comorbidity Index, CI: confidence intervals; CERAD: consortium to establish registry for alzheimer’s disease; Clinician-rated Anti-cholinergic Score (CR-ACHS); DAP: Drugs with 
anticholinergic properties; DBI: drug burden index; HR: hazard ratio; IADL – instrumental activities of daily living; LOS: Length of stay; MMSE: Mini-mental state examination; OR: Odd ratios; SD: 
standard deviation; SPPB: Short Physical Performance Battery Score   
 
 
